CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Javelin Pharmaceuticals Inc. (AMEX: JAV) announced that Dyloject® (diclofenac sodium solution for injection) has been accepted by the Scottish Medicines Consortium (SMC) for use within the National Health Service (NHS) Scotland, for the treatment or prevention of postoperative pain by intravenous injection, in supervised healthcare settings at the NHS Tariff Price of £48 per pack (10 x 75mg/2ml vials).
